Prof. Aichun Liu 刘爱春
Chief Physician, Professor
Department of Hematology and Lymphoma, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical management of blood disorders, lymphoma, and multiple myeloma. Hematopoietic stem cell transplantation. Biological immunotherapy for leukemia and lymphoma.
Dr. Liu is Chief Physician, Professor, and Director of the Ninth Internal Medicine Department. Holding a medical doctorate, Dr. Liu graduated from Harbin Medical University in 1987, earned a master’s degree in 1990, and a PhD from Niigata University (2002). Research fellowships included Stanford University (2004–2006) and studies at Shanghai Ruijin Hospital and Peking University Cancer Hospital (2007–2008).
Professional roles
- Member, Japanese Society of Hematology
- Member, Japanese Society of Clinical Hematology
- Member, American Society of Hematology
Name order: in Chinese the family name comes first (Liu Aichun). Papers usually list the name as Aichun Liu or Liu A.
Selected publications
40 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Cycle, 2026 (senior author): RBMS1 enhances PDPK1 mRNA stability to promote multiple myeloma malignancy and M2 macrophage polarization. PubMed 42277590
- Anticancer Drugs, 2026 (senior author): EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathway. PubMed 41243487
- Hematology, 2025 (senior author): Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram. PubMed 39722597
- Hematol Oncol, 2025 (senior author): Upregulated miR-29a-3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1. PubMed 40878597
- Front Biosci (Landmark Ed), 2024 (senior author): Joint Analysis of CCAAT/Enhancer-Binding Protein Beta and Interleukin 1 Beta in the Treatment and Prognosis of Diffuse Large B-Cell Lymphoma. PubMed 39614427
- Arch Biochem Biophys, 2024 (senior author): Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway. PubMed 38914215
- Ann Hematol, 2024 (senior author): Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through β-catenin by acting as targets of miR-495-3p. PubMed 38829410
- Discov Med, 2024 (senior author): Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma. PubMed 38531803
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion